Browse
Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Fahad Al-Juraibah in
Google Scholar
PubMed
Department of Paediatrics, Endocrine Division, Jeddah, Saudi Arabia
Search for other papers by Adnan Al Shaikh in
Google Scholar
PubMed
Search for other papers by Afaf Al-Sagheir in
Google Scholar
PubMed
Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Amir Babiker in
Google Scholar
PubMed
Search for other papers by Asma Al Nuaimi in
Google Scholar
PubMed
Search for other papers by Ayed Al Enezi in
Google Scholar
PubMed
Search for other papers by George S Mikhail in
Google Scholar
PubMed
Search for other papers by Hassan A Mundi in
Google Scholar
PubMed
Search for other papers by Hubert K Penninckx in
Google Scholar
PubMed
Search for other papers by Huda Mustafa in
Google Scholar
PubMed
Search for other papers by Majid Al Ameri in
Google Scholar
PubMed
Ministry of National Guard – Health Affairs, Riyadh, Saudi Arabia
Search for other papers by Mohamed Al-Dubayee in
Google Scholar
PubMed
Search for other papers by Nadia S Ali in
Google Scholar
PubMed
Faculty of medicine, Sohag University, Egypt
Search for other papers by Nagla Fawzy in
Google Scholar
PubMed
Search for other papers by Sameer Al Shammari in
Google Scholar
PubMed
Search for other papers by Tarek Fiad in
Google Scholar
PubMed
Summary
X-linked hypophosphatemic rickets (XLH), the most prevalent form of inherited hypophosphatemic rickets, is caused by loss-of-function mutations in the gene encoding phosphate-regulating endopeptidase homolog, X-linked (PHEX). This case series presents 14 cases of XLH from Gulf Cooperation Council (GCC) countries. The patients’ medical history, biochemical and radiological investigative findings, as well as treatment responses and side effects from both conventional and burosumab therapy, are described. Cases were aged 2–40 years at diagnosis. There were two male cases and 12 female cases. All cases were treated with conventional therapy which resulted in a lack of improvement in or worsening of the clinical signs and symptoms of rickets or biochemical parameters. Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients’ quality of life and adherence to treatment. In the 10 patients treated with burosumab, there was a marked improvement in the biochemical markers of rickets, with a mean increase in serum phosphate of +0.56 mmol/L and tubular maximum phosphate reabsorption (TmP) to glomerular filtration rate (GFR) ratio (TmP/GFR) of +0.39 mmol/L at 12 months compared to baseline. Furthermore, a mean decrease in serum alkaline phosphatase (ALP) of −80.80 IU/L and parathyroid hormone (PTH) of −63.61 pmol/L at 12 months compared to baseline was observed in these patients. Additionally, patients treated with burosumab reported reduced pain, muscle weakness, and fatigue as well as the ability to lead more physically active lives with no significant side effects of treatment.
Learning points
-
Conventional therapy resulted in a suboptimal response, with a lack of improvement of clinical signs and symptoms.
-
Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients’ quality of life and adherence to treatment.
-
Burosumab demonstrated marked improvements in the biochemical markers of rickets, in addition to reducing pain, muscle weakness, and fatigue.
-
There were no significant side effects associated with burosumab therapy.
Search for other papers by Tejal Patel in
Google Scholar
PubMed
Search for other papers by Rachel Longendyke in
Google Scholar
PubMed
Department of Pediatrics, George Washington School of Medicine, Washington, District of Columbia, USA
Search for other papers by Roopa Kanakatti Shankar in
Google Scholar
PubMed
Search for other papers by Nadia Merchant in
Google Scholar
PubMed
Summary
Iodine nutrition is a growing issue within the USA due to newer trends of non-iodized salts. There are no recent reviews looking at the current state of iodine deficiency-induced hypothyroidism in children in the USA. We performed a retrospective chart review at our tertiary pediatric endocrine clinic; four met the diagnostic criteria for iodine deficiency defined by a low urine iodine level. We further characterized severity of disease, risk factors, goiter, thyroid labs and antibodies. All cases had significant goiter and were diagnosed within the last 2 years. One case had iodine deficiency due to no iodized salt intake along with concurrent diagnosis of developmental delay and multiple food allergies, while others involved the use of non-iodized salts. Two cases had iodine deficiency along with autoimmunity. It is critical to obtain a dietary history for all patients who present with goiter and/or hypothyroidism. There may be a need to consider reevaluating current preventative measures for iodine deficiency, especially for certain vulnerable populations such as children who do not consume iodized salt.
Learning points
-
In recent decades, iodine nutrition has become a growing concern due to changing dietary patterns and food manufacturing practices.
-
A dietary history is crucial to obtain in children presenting with hypothyroidism and goiter, especially in children with restrictive diets due to behavioral concerns, developmental delays, or multiple food allergies.
-
Of the 12 different types of salts commercially available, only table salt contains iodine in an appropriate amount; thus, individuals using specialty salts can develop mild to moderate iodine deficiency-related thyroid disease.
Search for other papers by Stephanie Patrick in
Google Scholar
PubMed
Search for other papers by Deirdre James in
Google Scholar
PubMed
Summary
Thyroid cancer is one of the most common manifestations of Cowden syndrome, yet the syndrome is rare. The incidence of Cowden syndrome is 1 in 200,000. The diagnosis can be made clinically when patients present with a combination of symptoms such as mucocutaneous lesions with a strong personal or family history of thyroid, breast, endometrial, and colorectal cancer. A high index of suspicion is required to provide a clinical diagnosis utilizing major and minor criteria. Once a clinical diagnosis is made, genetic testing for a PTEN mutation, a tumor suppressor gene, is recommended. Cancer surveillance should be performed for those with positive genetic testing as well as those with negative genetic testing who still meet clinical diagnostic criteria. We present two cases of Cowden syndrome: one case involving an increasing number of thyroid nodules in a patient with known Cowden syndrome and another patient with a strong family history of cancer, personal history of follicular thyroid cancer, and numerous colonic polyps on screening colonoscopy. These cases demonstrate how early diagnosis of Cowden syndrome can help detect early cancer in both the patient and affected relatives.
Learning points
-
Diagnosing Cowden syndrome helps pre-risk stratification for early cancer screening.
-
The diagnosis of Cowden syndrome can be made with a combination of major and minor criteria: any two major criteria with or without a minor criterion; one major and one minor criterion; or three minor criteria.
-
Patients who meet the diagnostic criteria for Cowden syndrome should undergo genetic screening.
University of Glasgow, Glasgow, UK
Search for other papers by Natalie Below in
Google Scholar
PubMed
Search for other papers by Deborah Morrison in
Google Scholar
PubMed
Search for other papers by Ruth McGowan in
Google Scholar
PubMed
Search for other papers by Gregory C Jones in
Google Scholar
PubMed
Summary
A 20-year-old South Asian male presented with polyuria, polydipsia, HbA1c 81 mmol/mol, BMI 28.8 and family history of both type 1 and type 2 diabetes mellitus. As autoantibody testing was negative and c-peptide level demonstrated significant endogenous insulin secretion, type 1 diabetes was excluded. Given his age and family history, the differential diagnosis included maturity-onset diabetes of the young (MODY), a rare form of diabetes caused by a single-gene variant. A high probability of MODY was calculated and he was subsequently referred for genetic testing. Although a useful tool, the pre-test probability calculator for MODY is only validated in White Europeans. A heterogenous variant of unknown clinical significance of the NEUROD1 gene was detected, leading to gliclazide use with poor response. The patient responded well to metformin. Type 2 diabetes was considered the most likely diagnosis. This case highlights the diagnostic challenges in young patients of Asian ethnicity and the importance of interpreting genetic results of unknown significance within the clinical context. Ethnicity-specific BMI thresholds should be used when classifying patients as overweight or obese.
Learning points
-
Variants of unknown significance detected by genetic sequencing should be interpreted within the context of the patient’s other clinical parameters.
-
It is important to use ethnicity-specific BMI thresholds for obesity.
-
Diagnosis of type 2 diabetes mellitus at younger ages is becoming increasingly common.
-
The pre-test probability calculator for MODY is only validated in White Europeans; although a useful guide, results should be interpreted with caution in patients of other ethnicities.
Search for other papers by Sumeet Arora in
Google Scholar
PubMed
Search for other papers by Olga Yeliosof in
Google Scholar
PubMed
Search for other papers by Vivian L Chin in
Google Scholar
PubMed
Summary
Kallmann syndrome (KS) is a genetically heterogeneous condition characterized by hypogonadotropic hypogonadism with coexisting anosmia or hyposmia along with potential other phenotypic abnormalities depending on the specific genetic mutation involved. Several genetic mutations have been described to cause KS. The ANOS1 (KAL1) gene is responsible for 8% of mutations causing KS. A 17-year-old male presented to our clinic with delayed puberty and hyposmia, along with a family history suggestive of hypogonadism in his maternal uncle. Genetic testing for KS revealed complete exon 3 deletion in the ANOS1 gene. To the best of our knowledge, this specific mutation has not been previously described in the literature.
Learning points
-
Missense and frameshift mutations in the KAL1 or ANOS1 gene located in the X chromosome are responsible for 8% of all known genetic mutations of Kallmann syndrome.
-
Exon 3 deletion is one of the ANOS1 gene is a novel mutation, not reported before.
-
Targeted gene sequencing for hypogonadotropic hypogonadism can be employed based on the phenotypic presentation.
Search for other papers by Osamu Horikawa in
Google Scholar
PubMed
Department of Medicine, Omihachiman Community Medical Center, Omihachiman, Shiga, Japan
Search for other papers by Satoshi Ugi in
Google Scholar
PubMed
Search for other papers by Tomofumi Takayoshi in
Google Scholar
PubMed
Search for other papers by Yasushi Omura in
Google Scholar
PubMed
Search for other papers by Maya Yonishi in
Google Scholar
PubMed
Search for other papers by Daisuke Sato in
Google Scholar
PubMed
Search for other papers by Yukihiro Fujita in
Google Scholar
PubMed
Search for other papers by Tomoya Fuke in
Google Scholar
PubMed
Search for other papers by Yushi Hirota in
Google Scholar
PubMed
Search for other papers by Wataru Ogawa in
Google Scholar
PubMed
Search for other papers by Hiroshi Maegawa in
Google Scholar
PubMed
Summary
A 17-year-old boy was referred to our endocrinology clinic for a clinical investigation of hyperinsulinemia. An oral glucose tolerance test showed plasma glucose concentrations in the normal range. However, insulin concentrations were considerably elevated (0 min: 71 μU/mL; 60 min: 953 μU/mL), suggesting severe insulin resistance. An insulin tolerance test confirmed that he had insulin resistance. There was no apparent hormonal or metabolic cause, including obesity. The patient had no outward features of hyperinsulinemia, including acanthosis nigricans or hirsutism. However, his mother and grandfather also had hyperinsulinemia. Genetic testing showed that the patient (proband), his mother, and his grandfather had a novel p.Val1086del heterozygous mutation in exon 17 of the insulin receptor gene (INSR). Although all three family members have the same mutation, their clinical courses have been different. The onset of the mother’s diabetes was estimated at 50 years, whereas the grandfather developed diabetes at 77 years.
Learning points
-
Type A insulin resistance syndrome is caused by mutations in the insulin receptor (INSR) gene and results in severe insulin resistance.
-
Genetic evaluation should be considered in adolescents or young adults with dysglycemia when an atypical phenotype, such as severe insulin resistance, or a relevant family history is observed.
-
Clinical courses may differ even if the same genetic mutation is found in a family.
Search for other papers by Micah A Fischer in
Google Scholar
PubMed
Search for other papers by Ghada A Elmahmudi in
Google Scholar
PubMed
Search for other papers by Bracha K Goldsweig in
Google Scholar
PubMed
Search for other papers by Salaheddin H Elrokhsi in
Google Scholar
PubMed
Summary
Multiple research studies address the anti-insulinemic effect of growth hormone (GH). We report a case of a patient with anterior hypopituitarism on GH replacement who later developed type 1 diabetes mellitus (T1DM). Recombinant human growth hormone (rhGH) therapy was discontinued at the time of growth completion. Because of significantly improved glycemic control, this patient was weaned off subcutaneous insulin. He regressed from stage 3 to stage 2 T1DM and remained in this status for at least 2 years and until the writing of this paper. The diagnosis of T1DM was established based on relatively low C-peptide and insulin levels for the degree of hyperglycemia as well as seropositivity of zinc transporter antibody and islet antigen-2 antibody. Additional laboratory data obtained 2 months after discontinuing rhGH revealed improved endogenous insulin secretion. This case report calls attention to the diabetogenic effect of GH therapy in the setting of T1DM. It also demonstrates the possibility of regression from stage 3 T1DM requiring insulin therapy to stage 2 T1DM with asymptomatic dysglycemia after discontinuing rhGH.
Learning points
-
Given the diabetogenic effect of growth hormone, blood glucose levels should be monitored in patients with type 1 diabetes mellitus (T1DM) on insulin therapy and recombinant human growth hormone (rhGH) replacement.
-
Clinicians should closely monitor for risk of hypoglycemia after discontinuing rhGH among T1DM patients who are on insulin treatment.
-
The discontinuation of rhGH in the setting of T1DM may cause regression of symptomatic T1DM to asymptomatic dysglycemia requiring no insulin treatment.
Search for other papers by Wenxin Zhang in
Google Scholar
PubMed
Search for other papers by Wenqiong Xu in
Google Scholar
PubMed
Summary
Immune checkpoint inhibitors (ICPis) are novel immunotherapy drugs for a variety of cancers. Toripalimab is one of the ICPis that selectively blocks programmed death 1 (PD-1) and has been used for the treatment of malignant cancers in the hospitals of China. But with the widespread use of ICPis, some of the adverse reactions have gradually appeared. One of the most serious side effects is diabetes mellitus which is a relatively rare immune-related adverse event (irAEs) with life-threatening complications. We report a case of diabetes after the administration of toripalimab for the treatment of melanoma in southern China. To our knowledge, this is a rare case of diabetes occurring during toripalimab therapy, there is only one similar case reported in China so far. As China has a high morbidity of malignant cancer, a significant number of patients could be affected by the adverse reactions of using ICPis. Therefore, when ICPis are administrated, it is very important for clinicians to pay attention to one of the serious side effects – diabetes mellitus. Insulin therapy is often necessary after the diagnosis of ICPis-related diabetes, which has been proved as an effective method to prevent diabetic ketoacidosis (DKA) and other life-threatening complications in these patients.
Learning points
-
Toripalimab can cause the diabetes mellitus.
-
ICPis-related diabetes is treated primarily with insulin.
-
Immune checkpoint inhibitors cause diabetes by primarily destroying islet β cells.
-
There is not enough evidence to demonstrate that diabetic autoantibodies are related to diabetes caused by ICPis.
-
In addition to focusing on the efficacy of PD-1 inhibitor therapy, it is also necessary to pay attention to its adverse reactions, such as ICPis-related diabetes mellitus.
Search for other papers by João Felipe Queiroz in
Google Scholar
PubMed
Search for other papers by Soraya Lopes Sader in
Google Scholar
PubMed
Search for other papers by Carina Marques Barroso in
Google Scholar
PubMed
Search for other papers by Guido de Paula Colares Neto in
Google Scholar
PubMed
Summary
We present an adolescent with X-linked hypophosphatemic rickets (XLH) with bone age advancement and its response to aromatase inhibitors (AIs). A male with XLH, confirmed with a deletion on the PHEX gene, received regular treatment since the first year of life with average growth velocity and height. He had bone age compatible with chronological age until 13 when he had a bone age advancement and a decrease in the predicted final height thought to be due to initiation of oral isotretinoin, which has been previously reported. Then, anastrozole was initiated and maintained concomitant to the rickets treatment for 2 years with bone age stabilization. He had no adverse effects or worsening of bone health markers. As a result, he maintained his height gain and improved his final height Z score compared with the predicted final height at initiating anastrozole. In conclusion, although AIs was a reasonable strategy to stabilize bone age and minimize height impairment, careful monitoring is mandatory to understand its benefits and effects on XLH patients.
Learning points
-
Although X-linked hypophosphatemic rickets patients have normal puberty, they can be affected by metabolic and environmental factors that may advance their bone age and impair the predicted final height, similar to the general population.
-
Isotretinoin may accelerate skeletal maturation during puberty in an adolescent with X-linked hypophosphatemic rickets.
-
Aromatase inhibitors showed to be a reasonable strategy to stabilize bone age and minimize height impairment in an adolescent with X-linked hypophosphatemic rickets.
Search for other papers by David Lin in
Google Scholar
PubMed
Search for other papers by Jai Madhok in
Google Scholar
PubMed
Search for other papers by Jason Bouhenguel in
Google Scholar
PubMed
Search for other papers by Frederick Mihm in
Google Scholar
PubMed
Summary
We describe a case of a 47-year-old patient who presented with severe lactic acidosis, troponinemia, and acute kidney injury after receiving 8 mg of intramuscular dexamethasone for seasonal allergies in the setting of an undiagnosed epinephrine-secreting pheochromocytoma. This case was atypical, however, in that the patient exhibited only mildly elevated noninvasive measured blood pressures. Following a period of alpha-adrenergic blockade, the tumor was resected successfully. Steroid administration can precipitate pheochromocytoma crisis that may present unusually as in our patient with mild hypertension but profound lactic acidosis.
Learning points
-
Steroids administered via any route can precipitate pheochromocytoma crisis, manifested by excessive catecholamine secretion and associated sequelae from vasoconstriction.
-
Lack of moderate/severe hypertension on presentation detracts from consideration of pheochromocytoma as a diagnosis.
-
Lactatemia after steroid administration should prompt work-up for pheochromocytoma, as it can be seen in epinephrine-secreting tumors.
-
Noninvasive blood pressure measurements may be unreliable during pheochromocytoma crisis due to excessive peripheral vasoconstriction.